SCHEMBL3354545

SCHEMBL3354545

Cc1nnc(-c2csc(C3(c4ccc(C(=O)NO)cc4)CC3)n2)n1C(C)C

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 9/20 0.36
CYP3A4 P08684 1/20 0.36
HDAC1 Q13547 11/20 0.35
HDAC7 Q8WUI4 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC4 P56524 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
HDAC3 O15379 4/20 0.33
NCOR2 Q9Y618 1/20 0.33
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CTSS P25774 1/20 0.33
HSD11B1 P28845 2/20 0.32
HDAC2 Q92769 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9910029 0.93 CDK2 (0.38) HDAC6CYP3A4HDAC8CTSLCTSB
SCHEMBL2699025 0.86 HDAC1 (0.42) HDAC6HDAC1HDAC7HDAC8HDAC4
SCHEMBL1919479 0.84 CDK2 (0.45) HDAC6HDAC1HDAC3HDAC2
SCHEMBL2698977 0.83 HDAC1 (0.41) HDAC1HDAC8HDAC3NCOR2HDAC2
SCHEMBL657839 0.81 HDAC6 (0.39) HDAC6HDAC1HDAC8HDAC3NCOR2
SCHEMBL9910025 0.78 CDK2 (0.53)
SCHEMBL1919482 0.75 HDAC6 (0.35) HDAC6HDAC1HDAC7HDAC8HDAC4
SCHEMBL1919031 0.75 HDAC1 (0.51) HDAC6HDAC1HDAC7HDAC8HDAC4
SCHEMBL1920586 0.75 HDAC6 (0.42) HDAC6HDAC1HDAC7HDAC8HDAC3
SCHEMBL1920158 0.72 ADORA3 (0.52) HDAC6KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US claimed
CN-102123987-A Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds GILEAD COLORADO INC 2011-07-13 CN claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed
WO-2010014611-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE HISTONE DEACETYLASE INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 HDAC6 7/4885CYP3A4 3229/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.